Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Build A Bear Workshop Inc (BBW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Build A Bear Workshop Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.42 (market cap $29.60B), while Build A Bear Workshop Inc trades at $37.1 (market cap $461.88M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 64.1× Build A Bear Workshop Inc's market cap, and Build A Bear Workshop Inc pays a 2.5% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | BBW | |
|---|---|---|
Market Cap | $29.60B | $461.88M |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $75.85 |
52-Week Low | $205.48 | $29.84 |
Enterprise Value | $27.56B | $561.32M |
Dividend Yield | — | 2.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
Build-A-Bear Workshop (BBW) trades at $36.09, down 3.14% today, but maintains strong fundamentals with a P/E of 8.63 and robust profitability metrics including 35.87% ROE. The stock shows technical bullish signals with moving averages supporting upward momentum, though RSI levels suggest potential near-term overbought conditions. Recent earnings beats and strategic product launches position the company for continued growth despite current price weakness.
BBW presents compelling value with analyst consensus price target of $62.50 representing 73% upside potential. The debt-free balance sheet, consistent dividend payments, and international expansion strategy support long-term growth, though near-term consumer spending pressures and competitive retail environment pose execution risks for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Build A Bear Workshop Inc
Build-A-Bear is a global retailer specializing in customizable stuffed animals. It offers an interactive make-your-own experience where customers choose, stuff, and dress their furry friends in-store or online.
Read more on BBW →
